Top Markets
#1 Seeker Seeker +134.80%
#2 AI XOVIA AI XOVIA +105.87%
#3 MowCat MowCat +70.14%
#4 Helium Helium +65.13%
#5 Cortex Cortex +62.84%
#6 Pons Pons +37.19%
#7 UnifAI Network UnifAI Network +32.97%
#8 Zora Zora +27.86%
#9 Zylo Ecosystem Zylo Ecosystem +20.74%
#10 Bounce Bounce +16.77%
Coin of the day
Seeker Seeker
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Jacobio Pharmaceuticals Group Co., Ltd. Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd.

1167
Classement en actions #11796
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm... Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
Prix de l'action
$0.84111496
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$657.90M
Changement (1 jour)
-0.75%
Changement (1 an)
-19.13%
Pays
CN
Échange Jacobio Pharmaceuticals Group Co., Ltd. (1167)

Catégorie

Healthcare
Bénéfices pour Jacobio Pharmaceuticals Group Co., Ltd. (1167)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Jacobio Pharmaceuticals Group Co., Ltd., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Jacobio Pharmaceuticals Group Co., Ltd. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH